Valeant Pharmaceuticals shares got a positive bounce Tuesday after the company announced that its restatement of financial results for 2014 and 2015 involve just $58 million US of sales to Philidor were recognized at the wrong time.
mardi 23 février 2016
Inscription à :
Publier les commentaires (Atom)
0 commentaires:
Enregistrer un commentaire